Fingolimod treatment promotes regulatory phenotype and function of B cells. - Wikidata - wikimedia - TriplyDB

Fingolimod treatment promotes regulatory phenotype and function of B cells.

Fingolimod treatment promotes regulatory phenotype and function of B cells.

http://www.wikidata.org/entity/Q41268957

about

B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions Cytokine-Defined B Cell Responses as Therapeutic Targets in Multiple Sclerosis The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis Heterogeneity of B Cell Functions in Stroke-Related Risk, Prevention, Injury, and Repair Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets.Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation Fingolimod promotes peripheral nerve regeneration via modulation of lysophospholipid signaling.Regulation of human glia by multiple sclerosis disease modifying therapies.Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis.Differential effects of FTY720 on the B cell compartment in a mouse model of multiple sclerosis.B cells and their cytokine activities implications in human diseases.Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management.B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence.Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis.Human regulatory B cells in health and disease: therapeutic potential.Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients.Deciphering the Role of B Cells in Multiple Sclerosis-Towards Specific Targeting of Pathogenic Function.Role of Immunological Memory Cells as a Therapeutic Target in Multiple Sclerosis.Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod.Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird's Eye View.Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier.[Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].

P2860

Q26770664-020E445F-27A2-4330-B2A8-41A663BAB244 Q26771459-5094D367-2A27-4386-A76C-0975A1430675 Q28073377-B843D64C-A1D0-4C39-9372-3DA42B5DD1EB Q28078211-44178C53-E40F-4D9E-9631-F451FE2B5D3B Q35671182-DAC51AA6-A450-47FB-9DBC-057DA4624279 Q36669117-A71ED05E-7F46-401A-A02B-6D31A14472B7 Q36957280-50391E5C-E759-4FD8-925E-F7B623FE5320 Q36991308-FA808D2B-8F61-4512-8A62-60390427C2FF Q38563863-DEBBE334-3F62-45D7-A970-3BB7044A3280 Q38606914-A494191C-D3F3-40FD-9209-95CEE1160B92 Q38664253-4DDBDF18-4D60-4CD7-8552-1E041F155386 Q38665740-108DC699-0BC6-4B86-A05A-1980E96953BB Q38690022-D9F5912F-B698-42C0-8F43-C604EE52A577 Q38795434-3DAC3CD2-7953-4E18-B0CB-62CF86651A12 Q39119839-F9326B77-0FB5-42CA-A42F-4F01B6C8E826 Q39156034-9646BCDB-D80A-41F0-90D7-F167DFCA96CB Q42491880-C0E115EF-4F54-4E77-8292-0A4491F2D3C6 Q47102132-C42F597D-B99E-4219-BA98-D20BFF8419EC Q47130362-B371C07E-840C-4348-8C7E-06C00E7A54FB Q49354326-FA634611-21E7-4EAF-BFEB-1D8BC6DD9B11 Q49884884-6B162FDD-829A-4AB5-9532-5CDD2B4CD6E1 Q50177856-975C1CEA-2D92-49D1-9B67-4F6B8D0F4EE2 Q52855510-ED3A471D-DF90-4B56-AFE0-D010ED045312

P2860

Fingolimod treatment promotes regulatory phenotype and function of B cells.

http://www.wikidata.org/entity/Q41268957

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Fingolimod treatment promotes regulatory phenotype and function of B cells.

@en

type

label

Fingolimod treatment promotes regulatory phenotype and function of B cells.

@en

prefLabel

Fingolimod treatment promotes regulatory phenotype and function of B cells.

@en

P1433

Q41268957-6BBC5032-60EC-4116-AD1D-04474BCA3EFF

P1476

Q41268957-7CB47337-4855-40A1-BB2D-87643961849C

P2093

Q41268957-18DC0DA6-4FC6-4147-BCBA-B6C166E7AE23

Q41268957-493E53D8-CBA8-4E3B-86A7-931B37B61478

Q41268957-4B899328-F31C-454D-9A97-C30D2BF6FDA1

Q41268957-6595F911-8CDA-471A-BD18-E4EFD3A638B9

Q41268957-90771A2E-6270-4ECA-A95E-C5D0217562FF

Q41268957-A27ECCD6-B750-474A-844A-9EAE4A8EC385

Q41268957-D03A5E96-459E-447C-B404-1B7741ADF128

Q41268957-D14DEFF5-49B7-42EF-890B-30545EE183DD

P2860

Q41268957-237241AA-F494-4548-BDAE-A1DFEF65F863

Q41268957-23D75B51-31FD-4441-A3AC-4DC12FC56822

Q41268957-25D3046F-6409-429F-B6B9-17444F47E30D

Q41268957-2F0B497E-AC8C-4871-A57E-E2DBFA3F1411

Q41268957-4821A8BB-DE21-4222-B30A-70D362ADF97D

Q41268957-585A6985-AD08-47F3-8F1D-62251816217C

Q41268957-67D20D26-A5A3-4710-B6A0-9C2D0B9C75A9

Q41268957-71D46EB9-9BF0-4309-A9BF-2A0F5D0E6BCA

Q41268957-7237D58C-8F21-461A-B73E-23AC39B16EEF

Q41268957-7D144C20-D0EA-4A4E-84E3-01F88C45774F

P304

Q41268957-4CC4E773-2F59-4D0D-8AF4-1A0A3149F1FD

P31

Q41268957-AB1C7B19-8FDF-440A-80A2-5B9828A1C821

P356

Q41268957-D4037F87-5C85-4983-83EB-01037D226BFE

P433

Q41268957-C99A6F3E-0238-4822-8B38-908F57E06172

P478

Q41268957-CB93E27C-F1EB-4BCE-A008-914FC17C772F

P50

Q41268957-341B60CB-0C42-4D57-A3DC-85DDDFC9DCD0

Q41268957-5AA03A21-DB08-4220-BF39-B6CB549236AC

P577

Q41268957-530EE42B-5987-4341-B534-082249E965A1

P5875

Q41268957-1A339675-42A9-4DC6-8223-67A49EE237FE

P698

Q41268957-6EC35C0F-9EA6-40B8-8CC5-30C135AD4020

P932

Q41268957-8A690ECA-3D73-4A9A-9903-A6B4B08D447D

P356

P1433

Annals of clinical and translational neurology

P1476

Fingolimod treatment promotes regulatory phenotype and function of B cells.

@en

P2093

Anita Posevitz-Fejfar

http://www.w3.org/2001/XMLSchema#string

Berit Grützke

http://www.w3.org/2001/XMLSchema#string

Brigitte T Wildemann

http://www.w3.org/2001/XMLSchema#string

Catharina C Gross

http://www.w3.org/2001/XMLSchema#string

Luisa Klotz

http://www.w3.org/2001/XMLSchema#string

Martin V B Herold

http://www.w3.org/2001/XMLSchema#string

Stephanie Hucke

http://www.w3.org/2001/XMLSchema#string

Thomas Dehmel

http://www.w3.org/2001/XMLSchema#string

P2860

S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

Defective sphingosine 1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammation

CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients.

B cells regulate autoimmunity by provision of IL-10.

Prevention of arthritis by interleukin 10-producing B cells.

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity

Pathogenic and regulatory roles for B cells in experimental autoimmune encephalomyelitis.

Not always the bad guys: B cells as regulators of autoimmune pathology.

P304

119-130

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ACN3.155

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Bernd C Kieseier

P577

2015-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270967648

http://www.w3.org/2001/XMLSchema#string

P698

25750917

http://www.w3.org/2001/XMLSchema#string

P932

4338953

http://www.w3.org/2001/XMLSchema#string